These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 18094221

  • 1. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone.
    Kim KA, Park PW, Liu KH, Kim KB, Lee HJ, Shin JG, Park JY.
    J Clin Pharmacol; 2008 Jan; 48(1):66-72. PubMed ID: 18094221
    [Abstract] [Full Text] [Related]

  • 2. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition.
    Nakagami T, Yasui-Furukori N, Saito M, Tateishi T, Kaneo S.
    Clin Pharmacol Ther; 2005 Jul; 78(1):43-51. PubMed ID: 16003291
    [Abstract] [Full Text] [Related]

  • 3. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
    Jung SM, Kim KA, Cho HK, Jung IG, Park PW, Byun WT, Park JY.
    Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
    [Abstract] [Full Text] [Related]

  • 4. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
    Leon Jd, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ.
    Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
    [Abstract] [Full Text] [Related]

  • 5. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
    Bork JA, Rogers T, Wedlund PJ, de Leon J.
    J Clin Psychiatry; 1999 Jul; 60(7):469-76. PubMed ID: 10453802
    [Abstract] [Full Text] [Related]

  • 6. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone.
    Hendset M, Molden E, Refsum H, Hermann M.
    J Clin Psychopharmacol; 2009 Dec; 29(6):537-41. PubMed ID: 19910717
    [Abstract] [Full Text] [Related]

  • 7. Effect of venlafaxine on the pharmacokinetics of risperidone.
    Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM.
    J Clin Pharmacol; 1999 Mar; 39(3):297-309. PubMed ID: 10073330
    [Abstract] [Full Text] [Related]

  • 8. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide.
    Park JY, Kim KA, Park PW, Park CW, Shin JG.
    Clin Pharmacol Ther; 2003 Oct; 74(4):334-40. PubMed ID: 14534520
    [Abstract] [Full Text] [Related]

  • 9. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers.
    Novalbos J, López-Rodríguez R, Román M, Gallego-Sandín S, Ochoa D, Abad-Santos F.
    J Clin Psychopharmacol; 2010 Oct; 30(5):504-11. PubMed ID: 20814331
    [Abstract] [Full Text] [Related]

  • 10. Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers.
    Mahatthanatrakul W, Nontaput T, Ridtitid W, Wongnawa M, Sunbhanich M.
    J Clin Pharm Ther; 2007 Apr; 32(2):161-7. PubMed ID: 17381666
    [Abstract] [Full Text] [Related]

  • 11. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
    Yagihashi T, Mizuno M, Chino B, Sato Y, Sakuma K, Takebayashi T, Takao T, Kosaki K.
    Hum Psychopharmacol; 2009 Jun; 24(4):301-8. PubMed ID: 19387994
    [Abstract] [Full Text] [Related]

  • 12. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats.
    Aravagiri M, Marder SR.
    Psychopharmacology (Berl); 2002 Feb; 159(4):424-31. PubMed ID: 11823895
    [Abstract] [Full Text] [Related]

  • 13. Transfer of risperidone and 9-hydroxyrisperidone into human milk.
    Ilett KF, Hackett LP, Kristensen JH, Vaddadi KS, Gardiner SJ, Begg EJ.
    Ann Pharmacother; 2004 Feb; 38(2):273-6. PubMed ID: 14742766
    [Abstract] [Full Text] [Related]

  • 14. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
    Gunes A, Spina E, Dahl ML, Scordo MG.
    Ther Drug Monit; 2008 Oct; 30(5):628-33. PubMed ID: 18708991
    [Abstract] [Full Text] [Related]

  • 15. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron.
    Villikka K, Kivistö KT, Neuvonen PJ.
    Clin Pharmacol Ther; 1999 Apr; 65(4):377-81. PubMed ID: 10223773
    [Abstract] [Full Text] [Related]

  • 16. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects.
    Park JY, Kim KA, Kang MH, Kim SL, Shin JG.
    Clin Pharmacol Ther; 2004 Mar; 75(3):157-62. PubMed ID: 15001966
    [Abstract] [Full Text] [Related]

  • 17. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
    Nieminen TH, Hagelberg NM, Saari TI, Pertovaara A, Neuvonen M, Laine K, Neuvonen PJ, Olkkola KT.
    Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618
    [Abstract] [Full Text] [Related]

  • 18. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.
    Yasui-Furukori N, Mihara K, Takahata T, Suzuki A, Nakagami T, De Vries R, Tateishi T, Kondo T, Kaneko S.
    Br J Clin Pharmacol; 2004 May; 57(5):569-75. PubMed ID: 15089809
    [Abstract] [Full Text] [Related]

  • 19. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
    Wang L, Yu L, Zhang AP, Fang C, Du J, Gu NF, Qin SY, Feng GY, Li XW, Xing QH, He L.
    J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
    [Abstract] [Full Text] [Related]

  • 20. The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.
    Stroh M, Palcza J, McCrea J, Marsilio S, Breidinger S, Panebianco D, Johnson-Levonas A, Kraft WK, Orford K, Murphy G, Agrawal N, Trucksis M, Wagner JA, Iwamoto M.
    Cancer Chemother Pharmacol; 2012 May; 69(5):1247-53. PubMed ID: 22290273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.